(Q34640536)

English

Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Co

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Co (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1 reference

based on heuristic

inferred from title

object named as

Mattheos Bobos

3

0 references

object named as

Urania Dafni

2

0 references

Athanasios Dimopoulos

object named as

Meletios A Dimopoulos

24

0 references

George Fountzilas

1

object named as

George Fountzilas

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Triantafyllia Koletsa

1 reference

ORCID Public Data File 2021

Anna Batistatou

5

object named as

Anna Batistatou

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Vassiliki Kotoula

4

object named as

Vassiliki Kotoula

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

20

object named as

Helen Gogas

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Despina Televantou

11

object named as

Despina Televantou

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Konstantine T Kalogeras

22

object named as

Konstantine T Kalogeras

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Dimitrios Pectasides

23

object named as

Dimitrios Pectasides

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Angelos Koutras

13

object named as

Angelos Koutras

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Epaminontas Samantas

15

object named as

Epaminontas Samantas

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Helena Linardou

21

object named as

Helena Linardou

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Eleni Timotheadou

12

object named as

Eleni Timotheadou

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

14

object named as

George Klouvas

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Charisios Karanikiotis

17

object named as

Charisios Karanikiotis

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Nikolaos Pisanidis

16

object named as

Nikolaos Pisanidis

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Ioannis Kostopoulos

8

object named as

Ioannis Kostopoulos

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Eleftheria Tsolaki

10

object named as

Eleftheria Tsolaki

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Nicholas Pavlidis

19

object named as

Nicholas Pavlidis

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

author name string

Ioannis Xanthakis

6

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Christos Papadimitriou

7

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Triantafillia Koletsa

9

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Ioanna Sfakianaki

18

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

language of work or name

0 references

publication date

28 March 2013

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

163

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

https://scigraph.springernature.com/pub.10.1186/1471-2407-13-163

0 references

Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

Multiplication of Chromosome 17 Centromere Is Associated with Prognosis in Patients with Invasive Breast Cancers Exhibiting Normal HER2 and TOP2A Status.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

Targeting anthracyclines in early breast cancer: new candidate predictive biomarkers emerge

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

Use of archived specimens in evaluation of prognostic and predictive biomarkers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

Cancer statistics, 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

The complexity of genotypic alterations underlying HER2-positive breast cancer: an explanation for its clinical heterogeneity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes--molecular basis for combination chemotherapy in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

Medical treatment of early breast cancer. III: chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

Culprit and victim -- DNA topoisomerase II.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

Tissue microarrays: a powerful tool for high-throughput analysis of clinical specimens: a review of the method with validation data.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

DNA topoisomerases: structure, function, and mechanism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

Tissue microarrays for high-throughput molecular profiling of tumor specimens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

Follow-up study of HER-2/neu amplification in primary breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

7 July 2018

Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-163

21 January 2018

Incidence of chromosomes 1 and 17 aneusomy in breast cancer and adjacent tissue: an interphase cytogenetic study

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-163

21 January 2018

Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-163

21 January 2018

Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-163

21 January 2018

Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-163

21 January 2018

Implications of rarity of chromosome 17 polysomy in breast cancer.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-163

21 January 2018

retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-163

21 January 2018

Topoisomerase IIalpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-163

21 January 2018

Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-163

21 January 2018

REporting recommendations for tumor MARKer prognostic studies (REMARK).

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-163

21 January 2018

Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-163

21 January 2018

Anthracyclines, HER2, and TOP2A: the verdict.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-163

21 January 2018

Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-163

21 January 2018

Prognostic value of TOP2A gene amplification and chromosome 17 polysomy in early breast cancer.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-163

21 January 2018

Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-163

21 January 2018

Human epidermal growth factor receptor 2 testing in 2010: does chromosome 17 centromere copy number make any difference?

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-163

21 January 2018

Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3621498

26 October 2018

HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-163

21 January 2018

The structure and evolution of centromeric transition regions within the human genome

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-163

21 January 2018

Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-163

21 January 2018

Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23537287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23537287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant chemotherapy for breast cancer--30 years later

1 reference

https://pubmed.ncbi.nlm.nih.gov/23537287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER-2, TOP2A and chromosome 17 alterations in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23537287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/23537287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification

1 reference

https://pubmed.ncbi.nlm.nih.gov/23537287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER-2/neu and topoisomerase IIa gene amplification and protein expression in invasive breast carcinomas: chromogenic in situ hybridization and immunohistochemical analyses

1 reference

https://pubmed.ncbi.nlm.nih.gov/23537287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clonal chromosome abnormalities in human breast carcinomas. I. Twenty-eight cases with primary disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23537287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Her-2/neu gene amplification in low to moderately expressing breast cancers: possible role of chromosome 17/Her-2/neu polysomy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23537287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23537287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system

1 reference

https://pubmed.ncbi.nlm.nih.gov/23537287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17

1 reference

https://pubmed.ncbi.nlm.nih.gov/23537287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation

1 reference

https://pubmed.ncbi.nlm.nih.gov/23537287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: a case series

1 reference

https://pubmed.ncbi.nlm.nih.gov/23537287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2407-13-163

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34640536&oldid=1743738240"